Non-viral gene therapy for spinal cord regeneration

Li Yao, Sheng Yao, William Daly, William Hendry, Anthony Windebank, Abhay Pandit

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations


Spinal cord injury (SCI) normally results in life-long disabilities and a broad range of secondary complications. Advances in therapeutic delivery during the past few decades offer hope for such victims. However, the limited functional improvement shown in in vivo studies hinders effective therapeutic application in clinical practice. Recent studies showed that gene vectors can transfect cells present in the lesion of an injured spinal cord (endogenous cells) and thereby produce therapeutic molecules with long-lasting biological effects that promote neural tissue regeneration. In this article we review recent advances in non-viral gene delivery into neural cells and their use for gene therapy in SCI.

Original languageEnglish (US)
Pages (from-to)998-1005
Number of pages8
JournalDrug Discovery Today
Issue number17-18
StatePublished - Sep 2012

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Non-viral gene therapy for spinal cord regeneration'. Together they form a unique fingerprint.

Cite this